Representing Sun Pharma and Ranbaxy in a putative class action litigation where plaintiffs allege that Ranbaxy made fraudulent misrepresentations to the FDA, which led to its receipt of tentative approval to manufacture generic versions of Nexium®, Valcyte® and Diovan®.
Representing Amneal Pharmaceuticals, Sun Pharmaceuticals, and Upsher-Smith Laboratories in a class action litigation where plaintiff has alleged the existence of anti-competitive reverse payments resulting from multiple patent litigation settlements concerning the Alzheimer’s drug Namenda®. A settlement has been preliminarily approved by the court.
Representing Teva Pharmaceuticals in breach of contract litigation arising out of an alleged failure to use commercially reasonable efforts to market a drug.
Representing Exelon and its officers in a putative securities class action related to allegedly unlawful lobbying activities involving a subsidiary and federal investigations.
Represented corporate investors in oil and gas venture in litigation asserting claims against former business partners for conspiracy, tortious interference with business relations, fraud, and breach of contract, and defended investors in litigations commenced in multiple jurisdictions pertaining to the same investment agreements.
Represented health insurance company in putative class actions where plaintiffs asserted violations of ERISA, RICO, and various state consumer and antitrust claims relating to use of specialty networks in assessing insurance claims.
